# US 6,001,371 A · Parvovirus capsids > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,001,371 A - Document ID: US6001371A - Status: Granted - Kind: A - Application number: 08/462,464 - Filed: 1995-06-05 - Granted: 1999-12-14 - Earliest claimed: 1988-11-14 - Assignees: The United States of America as represented by the Department of Health and Human Services - Inventors: Neal S. Young; Sachiko Kajigaya; Takashi Shimada - Web page: https://patentgrep.com/patent/US6001371A ## CPC - C07K 14/005: from viruses - A61P 31/02: Local antiseptics - C07K 16/081: DNA viruses - C12N 15/86: Viral vectors - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C12N 2710/14043: viral genome or elements thereof as genetic vectore - C12N 2750/14222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2750/14223: Virus like particles [VLP] - C12N 2750/14243: viral genome or elements thereof as genetic vector - Y10S 977/803: Containing biological material in its interior - Y10S 977/917: Vaccine - Y10S 977/918: Immunological - Y10S 977/92: Detection of biochemical - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids. ## Claims ### Claim 1 An immunogenic composition comprising: a pharmaceutically acceptable carrier and an immunogenically effective amount of empty B19 parvovirus capsids. ### Claim 2 (depends on 1) The composition of claim 1 wherein the B19 parvovirus capsid has a VP1 minor structural protein to VP2 major structural protein ratio higher than the ratio of the naturally occurring full capsid. ### Claim 3 (depends on 2) The composition of claim 2 wherein the VP1 minor structural protein comprises at least about 5% of the protein in the capsid. ### Claim 4 (depends on 2) The composition of claim 2 wherein the VP1 minor structural protein comprises about 25 to 30% of the protein in the capsid. ### Claim 5 (depends on 1) A process for inducing antibodies against B19 parvovirus in a mammal comprising administering to the mammal the composition of claim 1. ### Claim 6 (depends on 5) The process of claim 5 wherein the B19 parvovirus capsid has a VP1 minor structural protein to VP2 major structural protein ratio higher than the ratio of the naturally occurring full capsid. ### Claim 7 (depends on 6) The process of claim 6 wherein the VP1 minor structural protein comprises at least about 5% of the protein in the capsid. ### Claim 8 (depends on 6) The process of claim 6 wherein the VP1 minor structural protein comprises about 25 to 30% of the protein in the capsid. ### Claim 9 A composition for inducing neutralizing antibodies in a mammal, comprising a pharmaceutically acceptable carrier and an effective amount of empty B19 parvovirus capsids containing VP1 minor structural protein and VP2 major structural protein. ### Claim 10 (depends on 9) The composition of claim 9 wherein the B19 parvovirus capsid has a VP1 minor structural protein to VP2 major structural protein ratio higher than the ratio of the naturally occurring full capsid. ### Claim 11 (depends on 10) The composition of claim 10 wherein the VP1 minor structural protein comprises at least about 5% of the protein in the capsid. ### Claim 12 (depends on 10) The composition of claim 10 wherein the VP1 minor structural protein comprises about 25 to 30% of the protein in the capsid. ### Claim 13 (depends on 9) A process for inducing neutralizing antibodies against B19 parvovirus infection in a mammal comprising administering to the mammal the composition of claim 9. ### Claim 14 (depends on 13) The process of claim 13 wherein the B19 parvovirus capsid has a VP1 minor structural protein to VP2 major structural protein ratio higher than the ratio of the naturally occurring full capsid. ### Claim 15 (depends on 14) The process of claim 14 wherein the VP1 minor structural protein comprises at least about 5% of the protein in the capsid. ### Claim 16 (depends on 14) The process of claim 14 herein the VP1 minor structural protein comprises about 25 to 30% of the protein in the capsid.